EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of In Vitro Efficiency of Ciclopirox Against Yersinia pestis and Francisella tularensis

Idan Hefetz, Raphael Ber, David Gur, Yoav Gal

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27042081 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Idan Hefetz und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness Ziona 7410001, Israel. Hauptthemen laut MEDLINE: Yersinia pestis, Francisella tularensis, Ciclopirox, Anti-Bacterial Agents. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Yersinia pestis and Francisella tularensis are Tier-1 pathogens with high interest for biodefense and public health. Evaluating the antibacterial activity of repurposed drugs against these high-priority pathogens is a key element in the ongoing effort to develop diversified antimicrobial strategies. Drug repurposing offers a cost-effective and time-efficient approach to address antibiotic resistance by identifying new applications for existing therapeutics. In this study, we demonstrate in vitro antibacterial effect of the antifungal agent ciclopirox and offer this drug as a potential antibacterial treatment. Ciclopirox in vitro activity was previously reported against various Gram-negative bacteria, including resistant strains, primarily through iron chelation that disrupts key metabolic pathways and virulence mechanisms. Additionally, it exhibits antibiofilm activity and can potentiate the efficacy of certain antibiotics. Our findings reveal that ciclopirox effectively inhibits the in vitro growth of fully virulent strains of Y. pestis and F. tularensis, as well as avirulent isolates, including avirulent mutants that their wild-type susceptibility was reduced through selection to MIC levels defining them as “nonsusceptible” to ciprofloxacin (Y. pestis Kim53Δ70Δ10 and F. tularensis LVS) and doxycycline (LVS), or resistant to doxycycline (Kim53Δ70Δ10) according to CLSI interpretive criteria. Additionally, prolonged exposure of Y. pestis and F. tularensis to sub-MIC and MIC concentrations of ciclopirox did not lead to an increase in observed MIC during the study period. These results highlight ciclopirox as a potential candidate for treatment alternative, combined with other antibiotic substances or repurposed drugs against these bacterial threats.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Yersinia pestisFrancisella tularensisCiclopiroxAnti-Bacterial AgentsMicrobial Sensitivity TestsBiofilmsAnimalsCiprofloxacin

Stichwörter der Autor:innen

Francisella tularensisYersinia pestisantibiotics-resistanceciclopiroxdrug repurposing

Substanzen

CiclopiroxAnti-Bacterial AgentsCiprofloxacin

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness Ziona 7410001, Israel.

Zitieren

APA

Hefetz, I., Ber, R., Gur, D., & Gal, Y. (2026). Evaluation of In Vitro Efficiency of Ciclopirox Against Yersinia pestis and Francisella tularensis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27042081

Vancouver

Hefetz I, Ber R, Gur D, Gal Y. Evaluation of In Vitro Efficiency of Ciclopirox Against Yersinia pestis and Francisella tularensis. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27042081

BibTeX
@article{Hefetz2026,
  author = {Hefetz, Idan and Ber, Raphael and Gur, David and Gal, Yoav},
  title = {Evaluation of In Vitro Efficiency of Ciclopirox Against Yersinia pestis and Francisella tularensis},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27042081}
}
Kostenlos starten →